New Anti-VEGF treatment has positive results in first clinical trial
age-related macular degeneration

New Anti-VEGF treatment has positive results in first clinical trial

EyePoint Pharmaceuticals recently announced results of the Phase 1 clinical trial of their new wet age-related macular degeneration treatment, EYP-1901.
Port Delivery System therapy looking for FDA approval
age-related macular degeneration

Port Delivery System therapy looking for FDA approval

The new device offers a continuous therapeutic dose of ranibizumab to the eye in place of regular eye injections.
5 Eye Diseases that can lead to Blindness
age-related macular degeneration

5 Eye Diseases that can lead to Blindness

There are five eye diseases that are the leading causes of blindness and low vision in the United States: age-related macular degeneration, cataracts, glaucoma, diabetic retinopathy and eye injurie...
Parkinson's drug may be a treatment for advanced age-related macular degeneration
AMD

Parkinson's drug may be a treatment for advanced age-related macular degeneration

Researchers discovered that levodopa is safe, well-tolerated and not only improved visual outcomes but also delayed anti-VEGF injections.
New technology detects Macular Degeneration
age-related macular degeneration

New technology detects Macular Degeneration

Researchers from the New York Eye and Ear Infirmary of Mount Sinai announced results of a study that analyzed the speed and accuracy of a new artificial intelligence (AI) algorithm in detecting ag...
New device provides early detection of macular degeneration
age-related macular degeneration

New device provides early detection of macular degeneration

The new technology will be helpful in providing an earlier diagnosis of age-related macular degeneration.
Eye Health News
age-related macular degeneration

Mice aren't human, but this could be important!

The journal Ophthalmology, compared the injection of Lucentis (ranibizumab) and Avastin (bevacizumab) into mice. Lucentis and Avastin had similar efficacy at suppressing sub-retinal neovascularizat...